GAITHERSBURG, Md., May 30, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the 2024 Jefferies Global Healthcare Conference.
Conference Details: | ||||||
Fireside Chat | ||||||
Date: | Thursday, June 6, 2024 | |||||
Time: | 12:30 – 12:55 p.m. Eastern Time (ET) | |||||
Location: | New York, NY | |||||
Moderator: | Roger Song, MD, CFA, Equity Research Analyst – Biotechnology | |||||
Novavax participant: | John C. Jacobs, President and Chief Executive Officer | |||||
Conference | ||||||
Event: | Investor Meetings | |||||
Date: | Thursday, June 6, 2024 | |||||
Recordings
A replay of the recorded fireside session will be available through the Events & Presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Giovanna Chandler
240-720-7804
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.32 |
| Daily Change: | 0.10 1.39 |
| Daily Volume: | 8,952,462 |
| Market Cap: | US$1.170B |
November 11, 2024 October 16, 2024 October 09, 2024 September 13, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
